Assembly Biosciences, Inc. (NASDAQ:ASMB) Major Shareholder Acquires $145,800.00 in Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) major shareholder Alexander Schornstein acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 8th. The stock was bought at an average price of $14.58 per share, with a total value of $145,800.00. Following the transaction, the insider now directly owns 703,113 shares in the company, valued at $10,251,387.54. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Assembly Biosciences Stock Performance

NASDAQ:ASMB opened at $16.05 on Friday. Assembly Biosciences, Inc. has a 12-month low of $7.69 and a 12-month high of $20.04. The stock’s 50 day moving average price is $15.57 and its two-hundred day moving average price is $14.71.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.98) EPS for the quarter, beating analysts’ consensus estimates of ($2.96) by $0.98. The company had revenue of $8.53 million during the quarter, compared to analyst estimates of $5.96 million. Equities analysts predict that Assembly Biosciences, Inc. will post -7.82 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Jefferies Financial Group upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $2.00 to $35.00 in a report on Friday, September 20th. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Tuesday, September 24th.

Institutional Investors Weigh In On Assembly Biosciences

Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC increased its position in shares of Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 7,690 shares during the period. Renaissance Technologies LLC grew its stake in Assembly Biosciences by 39.2% during the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after buying an additional 15,451 shares in the last quarter. Finally, Armistice Capital LLC bought a new position in Assembly Biosciences in the 2nd quarter valued at about $6,421,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.